So pardon the pun – “where’s the meat and what’s the price going to be”!
Thus, my mission continues … saying the "things" that need to be said, not whispered by those in the "know"!
April 8, 2016
Juno Therapeutics (JUNO) sets-up sub, JW Biotechnology (Shanghai) Co., Ltd with WuXi AppTec – HOLD post news
April 5, 2016
RegMed Investors: Beyond the news, don’t miss access to timely and actionable information
April 5, 2016
Bellicum Pharma (BLCM) Data shows BPX-501 Cells help adaptive immunity - BUY
April 1, 2016
RegMed Investors (RMi) it’s time to act on subscription!
March 31, 2016
Verastem (VSTM) Data supports FAK Inhibition in combination with Immunotherapy in patients with pancreatic cancer
March 31, 2016
Biostage ™ hits the limelight with a quantified focus - BUY
March 29, 2016
Caladrius Biosciences (CLBS) Treated 1st patient in P2 Type 1 Diabetes Trial
March 28, 2016
Opexa Therapeutics (OPXA) ATM initiation
March 24, 2016
Cytori Therapeutics (CYTX) P3 STAR study late-stage study of ECCS-50 in scleroderma 50% enrolled
March 24, 2016
Mesoblast (MESO ASX: MSB) Granted patent for cell-based treatment - BUY
March 23, 2016
Cytori Therapeutics (CYTX) Gets SME status by European Medicines Agency (EMA)
March 22, 2016
RegMed Investors’ (RMi) motto: Never leave an investor uninformed
March 22, 2016
uniQure (QURE) Pre-clinical data supports Huntington's disease gene therapy program
March 17, 2016
Kite Pharma (KITE) clinical collaboration with Roche Holdings’ (RHHBY) Genentech
March 17, 2016
Cellectis (CLLS) funds MabQuest research collaboration and license agreement
March 15, 2016
Capricor Therapeutics (CAPR) $4 M offering of 1.692 M shares at $2.40
March 14, 2016
Caladrius Biosciences (CLBS) subsidiary, PCT, sells 19.9% to Hitachi Chemical
March 10, 2016
Vericel (VCEL) positive top-line results from P2b ixCELL-DCM Ixmyelocel-T clinical trial
March 10, 2016
International Stem Cell Corporation (OTCQB: ISCO) private placement of $6.3 M
March 9, 2016
StemCells (STEM) Prices offering of $0.30 per share to raise $8.1 M?
March 9, 2016
Vericel (VCEL) new debt burden inhibits valuation
March 7, 2016
Vericel (VCEL) FDA Accepts Filing of BLA for MACI for the Treatment of Symptomatic Cartilage defects in the Knee
March 7, 2016
Spark Therapeutics (ONCE) acquires Genable Technologies
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his thirteenth (13th) year at RegMed Investors
© 2019 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.